Ocular Therapeutix Inc (NASDAQ:OCUL) Major Shareholder Summer Road Llc Buys 109,100 Shares of Stock

Ocular Therapeutix Inc (NASDAQ:OCUL) major shareholder Summer Road Llc acquired 109,100 shares of the stock in a transaction on Tuesday, March 24th. The shares were bought at an average price of $4.92 per share, for a total transaction of $536,772.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Summer Road Llc also recently made the following trade(s):

  • On Thursday, March 19th, Summer Road Llc acquired 40,900 shares of Ocular Therapeutix stock. The stock was bought at an average cost of $4.63 per share, with a total value of $189,367.00.
  • On Friday, March 13th, Summer Road Llc bought 210,800 shares of Ocular Therapeutix stock. The shares were bought at an average price of $4.63 per share, with a total value of $976,004.00.
  • On Tuesday, March 17th, Summer Road Llc bought 955,062 shares of Ocular Therapeutix stock. The shares were bought at an average cost of $5.00 per share, for a total transaction of $4,775,310.00.

NASDAQ OCUL traded up $0.03 during trading on Thursday, hitting $5.02. 11,696 shares of the company’s stock were exchanged, compared to its average volume of 1,861,353. The company has a market cap of $265.00 million, a PE ratio of -2.53 and a beta of 2.03. The company has a current ratio of 5.00, a quick ratio of 4.92 and a debt-to-equity ratio of 5.07. Ocular Therapeutix Inc has a fifty-two week low of $2.35 and a fifty-two week high of $8.12. The stock’s 50 day moving average price is $5.23 and its two-hundred day moving average price is $4.18.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.08). The company had revenue of $2.26 million during the quarter, compared to analyst estimates of $2.30 million. Ocular Therapeutix had a negative net margin of 2,043.34% and a negative return on equity of 801.90%. Analysts forecast that Ocular Therapeutix Inc will post -1.24 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new stake in Ocular Therapeutix in the third quarter valued at approximately $32,000. State Street Corp increased its holdings in shares of Ocular Therapeutix by 15.9% during the third quarter. State Street Corp now owns 672,896 shares of the biopharmaceutical company’s stock worth $2,046,000 after buying an additional 92,165 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Ocular Therapeutix in the 3rd quarter valued at $31,000. California State Teachers Retirement System lifted its stake in shares of Ocular Therapeutix by 11.5% in the 3rd quarter. California State Teachers Retirement System now owns 64,606 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 6,667 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at $44,000. 47.95% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently commented on OCUL. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, March 4th. Piper Sandler reiterated an “overweight” rating and set a $11.00 price target (up previously from $7.00) on shares of Ocular Therapeutix in a research report on Thursday, March 5th. Zacks Investment Research raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Friday, March 13th. ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Wednesday, March 18th. Finally, BidaskClub upgraded shares of Ocular Therapeutix from a “hold” rating to a “buy” rating in a research report on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Ocular Therapeutix currently has a consensus rating of “Buy” and a consensus price target of $7.00.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Featured Story: What is intrinsic value?

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.